Ten-year distant-recurrence risk prediction in breast cancer by CanAssist Breast (CAB) in Dutch sub-cohort of the randomized TEAM trial.

Breast Cancer Res · 2023 · PMC10103430 · PMID 37060036

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

Although CAB could stratify patients in both randomized arms, CAB performed much better in the exemestane arm than the sequential arm, with much higher HR, and a highly significant P -value.

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.